Journal article
A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer
Abstract
INTRODUCTON: The COU-AA-301 trial showed that abiraterone acetate (abiraterone), an oral cytochrome p450 CYP17 inhibitor, improved survival for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel. To better understand the non-clinical trial experience with abiraterone, we undertook a multicentre retrospective analysis of Canadian mCRPC patients treated with abiraterone.
METHODS: Consecutive patients with …
Authors
Clayton R; Wu J; Heng DY; North SA; Emmenegger U; Hotte S; Chi K; Zielinski R; Al-Shamsi H; Chen L
Journal
Canadian Urological Association Journal, Vol. 8, No. 9-10, pp. 583–590
Publisher
Canadian Urological Association Journal
Publication Date
September 2014
DOI
10.5489/cuaj.1891
ISSN
1911-6470